Home/Filings/4/0001415889-24-010604
4//SEC Filing

DAVIS STEPHEN 4

Accession 0001415889-24-010604

CIK 0001070494other

Filed

Apr 8, 8:00 PM ET

Accepted

Apr 9, 6:00 PM ET

Size

15.4 KB

Accession

0001415889-24-010604

Insider Transaction Report

Form 4
Period: 2024-04-05
DAVIS STEPHEN
EVP, CFO AND CBO
Transactions
  • Sale

    Common Stock

    2024-04-08$17.87/sh17,716$316,585144,267 total
  • Exercise/Conversion

    Common Stock

    2024-04-05+17,333136,175 total
  • Exercise/Conversion

    Common Stock

    2024-04-05+34,666170,841 total
  • Sale

    Common Stock

    2024-04-08$17.87/sh8,858$158,292161,983 total
  • Exercise/Conversion

    Restricted Stock Units

    2024-04-0534,666138,666 total
    Common Stock (34,666 underlying)
  • Exercise/Conversion

    Restricted Stock Units

    2024-04-0517,33334,667 total
    Common Stock (17,333 underlying)
Footnotes (6)
  • [F1]Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
  • [F2]The mandatory sales reported in this Form 4 were made to cover withholding taxes and tax related items imposed by the Issuer in connection with the vesting of restricted stock units, and it is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c).
  • [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.775 to $17.87, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
  • [F4]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.77 to $17.87, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
  • [F5]The restricted stock units vest in four equal annual installments beginning April 5, 2023.
  • [F6]Subject to accelerated vesting in certain circumstances, the restricted stock units vest as follows: 37.5% of the shares vest 18 months from April 5, 2022 (the "grant date"); 12.5% of the shares vest on the second anniversary of the grant date; and 25% of the shares vest on each of the third and fourth anniversaries of the grant date.

Issuer

ACADIA PHARMACEUTICALS INC

CIK 0001070494

Entity typeother

Related Parties

1
  • filerCIK 0001131146

Filing Metadata

Form type
4
Filed
Apr 8, 8:00 PM ET
Accepted
Apr 9, 6:00 PM ET
Size
15.4 KB